Abcuro
Michael McClain is Abcuro’s Clinical Trial Manager. He received his Bachelor of Science in Pharmaceutical Chemistry at UC Davis and his Doctor of Pharmacy at University of the Pacific. Additionally, he is currently in the last year of his MBA Program at Golden Gate University. Following pharmacy school, he started his career in the biopharmaceutical industry at BioMarin Pharmaceuticals working in the rare disease hemophilia area and transitioned to Gilead Sciences where he has worked in the inflammation IBD and early phase oncology area for the past two years. Michael has also been active in leading employee resource groups and managing PharmD internship and fellowship programs over the past several years of his career.
This person is not in any offices
Abcuro
2 followers
Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ABC008, a first-in-class anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy muscle tissue in patients with inclusion body myositis (IBM), into clinical studies.